These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975 [TBL] [Abstract][Full Text] [Related]
3. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981 [TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Anderson SD; Gums JG Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729 [TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367 [TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Barbour A; Schmidt S; Rand KH; Derendorf H Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449 [TBL] [Abstract][Full Text] [Related]
8. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698 [TBL] [Abstract][Full Text] [Related]
9. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364 [TBL] [Abstract][Full Text] [Related]
11. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Jones ME Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Craig WA; Andes DR Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887 [TBL] [Abstract][Full Text] [Related]
16. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100 [TBL] [Abstract][Full Text] [Related]
17. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Muller AE; Punt N; Mouton JW Antimicrob Agents Chemother; 2014 May; 58(5):2512-9. PubMed ID: 24514085 [TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Talbot GH; Thye D; Das A; Ge Y Antimicrob Agents Chemother; 2007 Oct; 51(10):3612-6. PubMed ID: 17682094 [TBL] [Abstract][Full Text] [Related]
20. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Stass H; Dalhoff A Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]